Firefly.png
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
August 22, 2024 09:00 ET | Firefly Neuroscience, Inc.
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...
FullLogo_Transparent_NoBuffer.png
Project Mosaic Launches to Bring “Biopsies” to ALS Drug Development
August 21, 2024 13:10 ET | Project Mosaic
Project Mosaic is proud to announce the launch of a groundbreaking initiative aimed at revolutionizing ALS drug development.
Firefly.png
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
August 21, 2024 09:00 ET | Firefly Neuroscience, Inc.
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
August 13, 2024 16:06 ET | Firefly Neuroscience, Inc.
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
engrail logo.png
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
August 08, 2024 07:00 ET | Engrail Therapeutics, Inc.
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
download.png
AIIR Consulting Announces Client Summit
July 31, 2024 11:00 ET | AIIR Consulting
The event promises to be a significant source of insights into contemporary leadership and development strategies.
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024 07:00 ET | Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
PN LOGO.jpg
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
July 23, 2024 09:00 ET | Precision Neuroscience
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a leader in developing brain–computer interface technology to restore function and autonomy for millions...
Jose-Alain Sahel and Botond Roska
Long-time collaborators Botond Roska and José-Alain Sahel win the Wolf Prize 2024 in the field of medicine Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy. The Wolf...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
June 26, 2024 16:05 ET | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs